跳至主要内容
临床试验/NL-OMON42735
NL-OMON42735已完成不适用

Characterization Of Resistance Against Live-attenuated diarrhoeagenic E. coli - CORA

IZO food research0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Ability to follow verbal and written instructions;
  • 2. Age between 18 and 55 years;
  • 3. Availability of internet connection;
  • 4. BMI >=20 and <=27 kg/m2;
  • 5. Healthy as assessed by the NIZO food research medical questionnaire;
  • 6. Male subjects;
  • 7. Signed informed consent;
  • 8. Voluntary participation;
  • 9. Willing to accept disclosure of the financial benefit of participation in the study to the authorities concerned;
  • 10. Willing to accept use of all encoded data, including publication, and the confidential use and storage of all data for at least 15 years;
  • 11. Willing to comply with study procedures;
  • 12. Willingness to abstain from high calcium containing products.
  • 13. Willingness to abstain from medications that contain acetaminophen, aspirin, ibuprofen, and other nonsteroidal anti-inflammatory drugs, (OTC) antacids and antimotility agents (eg, loperamide) on the three days before, during and 3 days after diarrhoeagenic E. coli challenge.
  • 14. Willingness to abstain from alcoholic beverages three days before, during and three days after diarrhoeagenic E. coli challenge.
  • 15. Willingness to give up blood donation starting 1 month prior to study start and during the entire study;

排除标准

  • 1. Disease of the GI tract, liver, bile bladder, kidney, thyroid gland (self-reported);
  • 2. Diarrhoeagenic E.coli strain (as used in the study) detected in fecal sample at screening;
  • 3. Evidence of current excessive alcohol consumption or non-therapeutic drug (ab)use);
  • 4. Evidence of IgA deficiency (serum IgA < 7 mg/dL or below the limit of detection of assay).
  • 5. High titer serum antibodies against CFA-II diarrhoeagenic E.coli strain (as used in the study) at screening;
  • 6. History of microbiologically confirmed ETEC or cholera infection in last 3 years.
  • 7. Known allergy to the following antibiotics: ciprofloxacin, trimethoprim-sulfamethoxazole, and penicillins.
  • 8. Mental status that is incompatible with the proper conduct of the study;
  • 9. Not having a general practitioner, not allowing disclosure of participation to the general practitioner or not allow to inform the general practitioner about abnormal results.
  • 10. Occupation involving handling of ETEC or Vibrio cholerae currently, or in the past 3 years.
  • 11. Participation in any clinical trial including blood sampling and/or administration of substances starting 1 month prior to study start and during the entire study;
  • 12. Personnel of NIZO food research, their partner and their first and second degree relatives;
  • 13. Reported average stool frequency of <1 or >3 per day;
  • 14. Symptoms consistent with Travelers' Diarrhoea concurrent with travel to countries where ETEC infection is endemic (most of the developing world) within 3 years prior to dosing, OR planned travel to endemic countries during the length of the study.
  • 15. Use of antibiotics, norit, laxatives (up till 6 months prior to inclusion), cholestyramine, antacids, H2 receptor antagonists or proton pump inhibitors or immune suppressive agents (up till 3 months prior to inclusion);
  • 16. Vaccination for or ingestion of ETEC, cholera, or E coli heat labile toxin within 3 years prior to inclusion;
  • 17. Vegetarians and vegans

研究者

发起方
IZO food research

相似试验